Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
2007

Evaluating Drug Prices and Access in Malaysia

Sample size: 100 publication 10 minutes Evidence: high

Author Information

Author(s): Babar Zaheer Ud Din, Ibrahim Mohamed Izham Mohamed, Singh Harpal, Bukahri Nadeem Irfan, Creese Andrew

Primary Institution: Universiti Sains Malaysia

Hypothesis

How do drug prices, availability, and affordability affect access to medicines in Malaysia?

Conclusion

The study found that medicine prices in Malaysia are significantly higher than international reference prices, leading to poor availability and affordability.

Supporting Evidence

  • Prices for innovator brands were found to be 16 times higher than international reference prices in private pharmacies.
  • Only 25% of generic medicines were available in the public sector.
  • A one-month treatment for peptic ulcer disease costs about a week's wages in the private sector.

Takeaway

In Malaysia, medicines are really expensive, making it hard for people to buy the ones they need. Even when they are free in hospitals, there aren't enough available.

Methodology

Data on drug prices and availability were collected from public hospitals, private pharmacies, and dispensing doctors using WHO-HAI methodology.

Potential Biases

Potential bias in data collection due to reliance on pharmacy students and the principal investigator.

Limitations

Some drugs were not recorded due to different strengths than specified, and low availability in the public sector may affect the robustness of the median price ratio.

Participant Demographics

The study included data from various geographical regions in West Malaysia.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040082

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication